Online Marketing Tools

Battered by a steep broad-market selloff this week, Moderna shares fell for a sixth straight day Friday as experts questioned whether Covid-19 vaccine sales alone will help justify the firm’s meteoric valuation, intensifying a crash that’s wiped out more than 60% of the value in one of last year’s top stocks and turned it into this year’s worst performer.

analyst, antibody, antiviral, biotech, cambridge, competitor, covid19, crash, data, expectation, flu, forecasting, inveestor, moderna, morganstanley, patients, stocks, trigger, vaccine, wallstreet